![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom
Received April 11, 2006; accepted June 7, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
CYP2D6. After correction for the loss of activity between the methods, the intrinsic activities of hepatic and intestinal CYP3A4, CYP2C9, CYP2C19, and CYP2D6 were comparable for the 16 pathways. The implications of these findings on the prediction of intestinal first-pass metabolism are discussed.
; Madani et al., 1999; Paine et al., 1999; Zhang et al., 1999; Glaeser et al., 2002; Matsumoto et al., 2002). Analogous to liver, CYP3A4 is the predominantly expressed P450 enzyme in the small intestine, accounting for 80% total P450 (Lin et al., 1999; Paine et al., 2006), followed by CYP2C9 (15%); however, the amount of CYP3A4 expressed (65.7 nmol) represents only 1% of the hepatic estimate (Paine et al., 1997; Yang et al., 2004). The expression of metabolic enzymes varies within the small intestinal villus with the highest found in mature enterocyte lining the villus tips (Kolars et al., 1994; Watkins, 1997). The zonal expression of the intestinal enzymes is more pronounced than in the liver, varying along its whole length, with the highest levels of CYP3A4 found in the proximal region of the intestine that decline distally opposite to the expression of P-glycoprotein; a similar trend was observed for CYP2C9 and CYP2C19 protein expression (Thummel et al., 1997; Läpple et al., 2003; Benet et al., 2004; Thörn et al., 2005).
Indirect assessment of intestinal metabolic ability (from p.o. and i.v. administration data) (Hall et al., 1999) indicates that the extent to which the CYP3A4 substrates are extracted by the intestine and liver varies considerably from drug to drug, in agreement with the lack of coordination in regulation of CYP3A4 expression in liver and intestine (Lown et al., 1994). In the case of alprazolam and quinidine, intestinal extraction is significantly lower compared with hepatic (Damkier et al., 1999; Hirota et al., 2001), whereas for certain substrates (e.g., triazolam, atorvastatin, and tacrolimus) intestinal extraction rivals or even exceeds that of the liver (Floren et al., 1997, Lennernas, 2003; Masica et al., 2004). The clinical relevance of the intestinal metabolism depends on the relative importance of the metabolic pathway involved and possible interplay with P-glycoprotein. The latter is particularly evident for low solubility/high permeability compounds (class 2 by Biopharmaceutics Drug Disposition Classification System) that are mutual substrates for P-glycoprotein and CYP3A4 (e.g., tacrolimus, cyclosporine), where the efflux via P-glycoprotein at the luminal membrane of the intestinal mucosa modulates intestinal CYP3A first-pass metabolism and the extent of oral bioavailability (Wu and Benet, 2005).
There have been several studies assessing the catalytic activity of intestinal P450 enzymes compared with the liver (Paine et al., 1997; Obach et al., 2001; von Richter et al., 2004). However, variability in the segment of the gut used (proximal or the whole length), source of the intestinal tissue (individual or pooled), different enterocyte isolation method, and observed interindividual variability in CYP3A4 expression in both liver and intestine (Kuehl et al., 2001; Lin et al., 2002) make an unequivocal comparison difficult.
The aim of the current study was to systematically evaluate the metabolic ability of five main metabolic enzymes in both human intestinal and hepatic microsomes. Intestinal microsomes prepared by mucosal scraping of the entire length of the intestine and pooled from 10 individuals were used. The study involved eight CYP3A substrates (midazolam, triazolam, diazepam, alprazolam, flunitrazepam, nifedipine, testosterone, and quinidine) and paclitaxel, tolbutamide, S-mephenytoin, and bufuralol as representative probes for CYP2C8, CYP2C9, CYP2C19, and CYP2D6 activity, respectively.
Comparison of the intrinsic catalytic activity between the hepatic and intestinal enzymes was performed by normalizing the Vmax [and consequently the intrinsic clearance (CLint) values] for the population relative abundance of the particular P450 enzyme. In addition, binding affinity and consistency in kinetic behavior were assessed for each of the 16 pathways under investigation, covering a wide range of clearance values. To investigate the impact of the enterocyte isolation method on the differential estimates of the P450 enzyme activity in the intestine, further studies were performed in the microsomes prepared by an enterocyte elution method. This was carried out at substrate concentrations corresponding to the previously determined Vmax values for 11 different pathways, including CYP3A4 and non-CYP3A4 probes.
The present study provides a comprehensive comparative analysis of the five different P450 enzymes in intestinal and hepatic microsomes using 12 different substrates and their respective pathways. A general agreement in the binding affinity and kinetic behavior between the hepatic and intestinal enzymes observed, irrespective of the P450 enzymes investigated, provides evidence of comparable intestinal and hepatic catalytic activity (per picomole of P450 enzyme) for CYP3A4, CYP2D6, CYP2C9, and CYP2C19, conditional to enterocyte isolation method.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-hydroxytestosterone, NADP, and isocitric dehydrogenase were purchased from Sigma Chemicals Co. (Poole, Dorset, UK). (3S)-3-hydroxyquinidine, oxidized nifedipine, 4'-hydroxymephenytoin, paclitaxel, bufuralol, 1'-hydroxybufuralol, 4-hydroxytolbutamide, and midazolam metabolites were obtained from Ultrafine Chemicals (Manchester, UK). Alprazolam and triazolam metabolites were purchased from BI-OMOL International (Plymouth Meeting, PA), and flunitrazepam metabolites were a gift from Roche (Basel, Switzerland). All the other reagents and solvents were of high analytical grade. Pooled intestinal microsomes (n = 10) prepared by mucosal scraping of the entire length of the gut were purchased from InVitroTechnologies (Baltimore, MD). Pooled intestinal microsomes prepared by enterocyte elution method were obtained from Xenotech (Kansas City, KS). Pooled liver microsomes (n = 22), 3'-hydroxypaclitaxel, and 6
-hydroxypaclitaxel were obtained from BD Gentest Co. (Woburn, MA). Incubation Conditions in the Human Intestinal Microsomes. The kinetic studies were performed in pooled human intestinal microsomes (HIM) (InVitroTechnologies) prepared by mucosal scraping of the entire length of the gut. Incubation times (10-90 min) and protein concentrations (0.5-1.5 mg/ml) were within the linear range for each individual substrate and are shown in the Table 1. Microsomes were suspended in phosphate buffer (0.1 M, pH 7.4) with the final incubation volume of 0.25 ml. Samples were preincubated for 5 min in a shaking water bath at 37°C, and each reaction was initiated with an NADPH regenerating system (1 mM NADP+, 7.5 mM isocitric acid, 10 mM magnesium chloride, and 0.2 units isocitric dehydrogenase). The final concentration of the organic solvent (acetonitrile or methanol) in incubation media was less than 1% v/v. Kinetic profiles for substrates investigated were generated from 10 to 12 substrate concentration points, overa1 to 1000 µM range. The reaction was terminated by 0.25 ml of ice-cold acetonitrile with 1 µM of the appropriate internal standard, and samples were centrifuged at 13,400g for 10 min and further analyzed by liquid chromatography/tandem mass spectrometry (LC/MS/MS).
|
Incubation Conditions in the Human Liver Microsomes. The kinetic studies were performed in pooled human liver microsomes (HLM) obtained from BD Gentest Co. Incubation times (5-60 min) and protein concentrations (0.25-1 mg/ml) were within the linear range for each individual substrate (Table 1). The incubation procedure, NADPH regenerating system, internal standard, and further analysis by LC/MS/MS were the same as described for the intestinal microsomes. The final concentration of the organic solvent (acetonitrile or methanol) in incubation media was less than 1% v/v. The substrate concentration range was the same as applied in the intestinal microsomal studies.
Comparison of the Intestinal Activity in Microsomes Prepared by Enterocyte Elution and Mucosal Scraping. To evaluate the impact of enterocyte isolation method on the intestinal activity, additional studies were performed in pooled intestinal microsomes prepared by elution method (Xenotech). The assessment was carried out at the substrate concentrations corresponding to the previously determined Vmax conditions for eight different substrates (at 50, 750, 250, 250, 500, 1000, 750, and 50 µM for midazolam, alprazolam, quinidine, testosterone, diazepam, tolbutamide, S-mephenytoin, and bufuralol, respectively). The 1 mg/ml protein concentration was used for all the substrates, except for midazolam, for which 0.5 mg/ml concentration was used; the incubation times were as described in Table 1. Of all the eight substrates, only midazolam's full kinetic profile was obtained at a substrate concentration range corresponding to the studies in intestinal microsomes prepared by mucosal scraping to compare the binding affinity and type of kinetics between two different methods. The incubation procedure and further analysis were as described for intestinal microsomes prepared by mucosal scraping. The extent of microsomal protein binding was determined using the microfiltration method for all the substrates, as described previously (Rawden et al., 2005).
LC/MS/MS. The method used for the analysis of midazolam, triazolam, alprazolam, diazepam, flunitrazepam, and quinidine was adapted from Galetin et al. (2004). The LC/MS/MS method applied for the analysis of testosterone, nifedipine, mephenytoin, and tolbutamide was described by Rawden et al. (2005).
Paclitaxel. 3'-Hydroxypaclitaxel, 6-hydroxypaclitaxel, and docetaxel were quantified by LC/MS/MS. Each metabolite pair, together with docetaxel as internal standard, was separated on a Luna phenyl hexyl 30 x 4.6-mm, 5-µm column (Phenomenex, Torrance, CA) at 40°C using a tertiary gradient maintained at 1 ml/min by a Waters Alliance 2795 HT LC system. An initial mobile phase of 78% 0.05% formic acid/22% acetonitrile was maintained for 1 min before being ramped linearly to 50% 0.05% formic acid/50% acetonitrile at 2 min and then immediately to 45% 0.05% formic acid/55% acetonitrile and 45% 0.001 M ammonium acetate/55% acetonitrile before being ramped linearly from 3 to 4 min to 22% 0.05% formic acid/78% acetonitrile. The initial ratio was immediately re-established at 4 min and maintained to 5 min. The retention times were approximately 3.4 (3'-hydroxypaclitaxel), 3.6 (6-hydroxypaclitaxel), and 3.75 (docetaxel) min. The compounds were detected and quantified by atmospheric pressure electrospray ionization MS/MS using a Micromass Quattro Ultima triple quadrupole mass spectrometer. The LC column eluate was split, and one-fourth was delivered into the MS where the desolvation gas (nitrogen) flow rate was 600 l/h, the cone gas (nitrogen) flow rate was 100 l/h, and the source temperature was 125°C. Using positive ion mode, protonated molecular ions were formed using a capillary energy of 3.5 kV and cone energies of 70 V (3'-hydroxypaclitaxel), 90 V (6-hydroxypaclitaxel), and 55 V (docetaxel). Product ions formed in argon at a pressure of 2 x 10-3 mbar and at collision energies of 10 eV (3'-hydroxypaclitaxel, m/z 870.25
302.1), 20 eV (6-hydroxypaclitaxel, m/z 870.25286.2), and 15 eV (docetaxel, m/z 808.35226.2) were monitored as ion chromatograms, which were integrated and quantified by quadratic regression of standard curves using Micromass QuanLynx 3.5 software.
Bufuralol. 1'-Hydroxybufuralol and dextromethorphan were quantified by LC/MS/MS. 1'-Hydroxybufuralol and dextromethorphan (internal standard) were separated on a Luna C18(2) 50 x 4.6-mm, 3-µm column (Phenomenex) at 40°C using a tertiary gradient maintained at 1 ml/min by a Waters Alliance 2795 HT LC system. An initial mobile phase of 90% 0.001 M ammonium acetate/10% acetonitrile was maintained for 1 min before being ramped immediately to 15.5% 0.05% formic acid/19.5% acetonitrile and 42.5% 0.001 M ammonium acetate/22.5% acetonitrile. This was maintained for 2 min before being ramped immediately to 13.5% 0.05% formic acid/1.5% acetonitrile and 8.5% 0.001 M ammonium acetate/76.5% acetonitrile and maintained for a further 1 min. The initial ratio was immediately re-established and maintained to 5 min. The retention times were approximately 2.35 (1'-hydroxybufuralol) and 2.47 (dextromethorphan) min. The compounds were detected and quantified by atmospheric pressure electrospray ionization MS/MS using a Micromass Quattro Ultima triple quadrupole mass spectrometer. The LC column eluate was split, and one-fourth was delivered into the MS where the desolvation gas (nitrogen) flow rate was 600 l/h, the cone gas (nitrogen) flow rate was 100 l/h, and the source temperature was 125°C. Using positive ion mode, protonated molecular ions were formed using a capillary energy of 3.5 kV and cone energies of 70 V (1'-hydroxybufuralol) and 89 V (dextromethorphan). Product ions formed in argon at a pressure of 2 x 10-3 mbar and at collision energies of 20 eV (1'-hydroxybufuralol, m/z 278.15186.1) and 40 eV (dextromethorphan, m/z 272.15171.35) were monitored as ion chromatograms, which were integrated and quantified by quadratic regression of standard curves using Micromass QuanLynx 3.5 software.
Data Analysis. The kinetic parameters for each substrate were obtained from untransformed data by nonlinear least-squares regression using GraFit 5 (Erithacus Software, Horley, Surrey, UK) using the Michaelis-Menten equation in case of hyperbolic kinetics. When the metabolic profile was consistent with positive homotropic behavior, Vmax, S50, and Hill coefficient (n) were calculated from untransformed data using the Hill equation. For those substrates, the maximal clearance (CLmax), when the enzyme is fully activated, was calculated instead of CLint as described previously (Houston and Kenworthy, 2000; Galetin et al., 2004).
Normalization of Vmax Values. To compare the intrinsic catalytic activity between the hepatic and intestinal enzymes, the Vmax values obtained (and consequently the CLint) were normalized for the mean population relative abundance of P450 enzymes involved. The values used are listed in Table 2 and were obtained by meta-analysis of the P450 abundance in 219 (CYP3A4), 174 (CYP2C9), 126 (CYP2C19), and 98 livers (CYP2D6) (Rowland Yeo et al., 2003) and 31 intestinal samples (Paine et al., 2006).
|
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-hydroxylation via CYP2C8 in the intestinal microsomes was negligible and was therefore not included in the further analysis.
|
), was also noted in the kinetic profiles obtained in the HIM for alprazolam, triazolam, testosterone, diazepam, and flunitrazepam. Alprazolam 1'- and 4-hydroxylation is shown as a representative example in Fig. 1A. The type of kinetics for the CYP3A and CYP2C19 substrates investigated was in general agreement with the previous reports (Nielsen et al., 1999; Wang et al., 2000; Hesse et al., 2001; Obach et al., 2001; Galetin et al., 2004; Rawden et al., 2005); the only significant difference was observed in the case of midazolam 4-hydroxylation, where in contrast to hyperbolic kinetics in hepatic microsomes, positive cooperativity was observed in the intestine. Kinetic profiles obtained for quinidine, tolbutamide, and S-mephenytoin showed standard Michaelis-Menten kinetics in both systems, whereas bufuralol followed biphasic kinetic behavior. Initial analysis indicated significantly lower activity in HIM compared with HLM as illustrated in the comparative clearance plots for 3-hydroxyflunitrazepam in Fig. 1B (50-fold lower maximal clearance in HIM compared with HLM). The characteristics of positive cooperativity were observed in the clearance plots for both systems; however, the flunitrazepam concentration at which the maximal clearance (corresponding to the fully activated enzyme) was achieved differs, which may be related to interdonor differences in the intestinal and hepatic pool. Both Km (or S50) and Vmax values for each individual pathway (in case of benzodiazepines) were compared between HIM and HLM. Km (or S50) values obtained in HIM were corrected for the microsomal binding (Table 3), with fu(m) values of 0.82, 0.64, 0.94, 0.61, 0.87, 0.67, 0.55, 0.59, and 0.31 for midazolam, diazepam, flunitrazepam, alprazolam, triazolam, quinidine, testosterone, nifedipine, and bufuralol, respectively; no corrections were applied for tolbutamide and S-mephenytoin (fu(m) > 0.95). Km (or S50) values obtained for testosterone, quinidine, and bufuralol in HLM were also corrected for the microsomal binding with fu(m) values of 0.78, 0.8, and 0.58, respectively. A 100-fold range in Km (S50) values observed in HIM was consistent with HLM. Of the 16 pathways investigated, 75% of Km (S50) values obtained in intestinal microsomes were within 2-fold of hepatic values (Fig. 2A). The maximal disagreement was observed in the case of S-mephenytoin and 1'-hydroxymidazolam, where the intestinal Km values were 3-fold greater than the hepatic estimates (Table 3).
|
|
In contrast, Vmax values in HIM were two orders of magnitude lower compared with HLM (0.0005-0.26 versus 0.04-6.4 nmol/min/mg protein, respectively). Nordiazepam, 1'-hydroxyalprazolam, and bufuralol formation were at the lower range, and 1'-hydroxymidazolam and testosterone were at the higher activity range (Table 3; Fig. 2B). Comparison of CLint (µl/min/mg protein) or CLmax (for sigmoidal kinetics) obtained in both in vitro systems for all of the 16 pathways investigated is shown in Fig. 3A. Clearance estimates for CYP3A4 substrates showed a wide range in both HLM (0.36-895 µl/min/mg protein) and HIM (0.006-22 µl/min/mg protein); in both systems alprazolam and midazolam 1'-hydroxylation resulted in the lowest and highest estimates, respectively (Table 3). Clearance obtained in HLM for CYP3A4 substrates was 16- to 180-fold higher (4-hydroxymidazolam and 4-hydroxyalprazolam, respectively) compared with HIM. In case of CYP2D6 and CYP2C substrates, the -fold difference in clearance estimates between the two in vitro systems ranged from 180 to 360 for bufuralol and tolbutamide, respectively. For most of the substrates investigated, the -fold difference in CLint between HLM and HIM reflected the differences observed in the Vmax values.
|
), whereas diazepam and flunitrazepam (3-hydroxy/N-desmethyl) pathway ratios were used to assess the CYP2C19 activity in the intestine and liver. In case of flunitrazepam and diazepam, the ratios showed noticeable substrate concentration dependence, but identical trends were observed in both in vitro systems (Fig. 4). Similar trend was observed with midazolam, in which pathway ratio decreased with the increasing substrate concentrations, with a comparable mean ratio of 5.2 and 5.6 in liver and intestine, respectively. The most evident changes in pathway ratios were noted over the range of alprazolam concentrations. The ratio of 4-/1'-hydroxyalprazolam decreased 5-fold in HIM, resulting in 1'-hydroxyalprazolam contributing 17% to the overall alprazolam clearance in HIM, in contrast to 4% observed in HLM.
|
; Paine et al., 2006). In contrast to expectation, the trend of lower clearance in HIM compared with the estimates in HLM (4.5-50-fold) remained (Fig. 3B). The clearance rank order was in good agreement between the systems, irrespective of the normalization for the CYP relative abundance.
Comparison of two enterocyte isolation methods (elution and mucosal scraping) showed systematically greater Vmax values for the CYP3A4 substrates in microsomes prepared from eluted enterocytes compared with mucosal scraping, ranging from 3- to 29-fold for 4-hydroxymidazolam and nordiazepam, respectively (Fig. 5A). The activity difference between the methods was P450-related, resulting in the following rank order: CYP2C19 > CYP3A4 > CYP2C9 CYP2D6. The mean activity ratio for each individual P450 is shown in Table 2. When the correction for the activity loss was applied to the clearance estimates obtained in intestinal microsomes prepared by mucosal scraping (an average 10-fold), the intrinsic catalytic activities (expressed per picomole CYP) of all four different P450 enzymes were comparable between the liver and intestine, as shown in the Fig. 3C. In case of tolbutamide, 4-hydroxyalprazolam, 3-hydroxydiazepam, and 1'-hydroxytriazolam intestinal clearance represented 20 to 33% of hepatic estimate, whereas intestinal CLint of 4-hydroxymidazolam was 2-fold greater than the hepatic counterpart (Table 4). The kinetic characteristics of 1'-hydroxymidazolam formation in both microsomes prepared by elution and mucosal scraping were comparable with the profile obtained in HLM (Fig. 5B). The enterocyte isolation method had no significant effect on midazolam 1'-hydroxylation Km, resulting in values of 10.1 and 8.2 µM obtained in mucosal scraping and elution microsomal data, respectively.
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
) and testosterone (Obach et al., 2001), the kinetics of these substrates was previously not documented for the gut. In addition, the potential role of "minor" intestinal P450, CYP2C8, CYP2C9, CYP2C19, and CYP2D6, was assessed.
The general agreement between the atypical kinetic profiles in the HIM and HLM showed that the extent of cooperative binding to the intestinal CYP3A4 was similar to hepatic counterpart for the substrates investigated. A comparative analysis indicated no significant differences in the binding affinity between intestinal and hepatic P450, illustrated by good agreement in the corresponding Km values (Fig. 2A) over a 130-fold range. In contrast, two orders of magnitude lower intestinal Vmax and consequently CL values were observed (Figs. 2B and 3A, respectively). The intestinal Vmax values obtained for the two most commonly used CYP3A4 in vitro probes, midazolam and testosterone, were comparable with the previous studies in microsomes prepared by scrapings from a variety of individual donors (5-31) (Prueksaritanont et al., 1996; Lin et al., 2002).
More than 20-fold variation in the CYP2C9 activity (assessed by either tolbutamide or diclofenac hydroxylation) has been reported in duodenal/jejunal microsomes (Prueksaritanont et al., 1996; Obach et al., 2001), consistent with the polymorphic nature of this enzyme. Although CYP2C9 represents the main CYP2C enzyme in the intestine (Läpple et al., 2003; Paine et al., 2006), its intestinal activity is indicated to be an order of magnitude lower than the hepatic complement (Prueksaritanont et al., 1996). The tolbutamide Vmax obtained in our study is within the reported range; however, the tolbutamide intestinal Vmax and CL represented only 0.6 and 0.3% of hepatic (data not normalized for CYP2C9 relative abundance). Mephenytoin 4'-hydroxylation Vmax obtained in the current study was at the lower end of the reported values (0.3-13.1 pmol/min/mg protein) (Obach et al., 2001; Läpple et al., 2003).
However, a direct comparison of the current and previously reported intestinal data is not straightforward because a number of variables may contribute to the differential estimates of the P450 activity in the intestine. Use of different segments of gut (proximal region versus the whole length in the pooled microsomes) provides one reason for the inconsistencies seen across the studies. The enterocyte microsomal yield is a function of the gut segment used, and the highest abundance and activity are observed in the proximal regions; therefore, the use of pooled intestinal microsomes from various sections of the gut might represent a limitation due to the greater intestinal heterogeneity compared with the liver. The effect of CYP2C polymorphism, the coregulation between CYP2C9 and CYP3A4, and the impact of a number of various dietary compounds on intestinal CYP3A4 are unknown in the pooled samples used in our study; all of these factors may have affected the activity of intestinal enzymes.
Most of the previous assessments of intestinal metabolic activity were performed at a single point or using a limited substrate concentration range of the representative probe (Prueksaritanont et al., 1996; Obach et al., 2001; Lin et al., 2002). In case of CYP3A4, different marker probes were used, namely, midazolam (Paine et al., 1997; Lin et al., 2002), testosterone (Prueksaritanont et al., 1996; Obach et al., 2001), and verapamil (von Richter et al., 2004), resulting in differential extent of reported interindividual variability in the intestinal CYP3A4 activity (7-168-fold difference). In addition, the most common method of assessment of intestinal activity is based on the comparison of hepatic and intestinal activity expressed per milligram of microsomal protein (Paine et al., 1997; von Richter et al., 2004) rather than as catalytic activity (normalized for the relative abundance of the P450 investigated). Comparison of catalytic activity as a measure of intrinsic enzyme activity in case of verapamil (Yang et al., 2004) showed evidence of similar intestinal and hepatic CYP3A4 intrinsic activities.
The current study provides the first systematic comparison of the hepatic and intestinal intrinsic metabolic activity for CYP3A4, CYP2C9, CYP2C19, and CYP2D6 (CYP2C8 not included because of negligible activity) for a range of substrates. Population relative abundance of the P450 enzymes (Table 2) was used for the normalization of Vmax and CL data; this approach was considered appropriate because pooled microsomes from different donors were used for the assessment of both intestinal and hepatic activity. Although the incorporation of the P450 relative abundance increased the overall contribution of the intestinal clearance compared with the liver, intestinal clearance for CYP3A4 substrates remained 4.5- to 50-fold lower compared with the estimates in the liver. An 11- to 40-fold lower activity was observed for non-CYP3A4 probes, bufuralol and S-mephenytoin, respectively (Fig. 3B). The rank order in clearance was consistent between the systems over the range covered (0.002-5.8 and 0.0002-0.52 µl/min/pmol CYP in HLM and HIM, respectively), irrespective of the P450 enzyme investigated.
The process of enterocyte isolation (mucosal scraping and enterocyte elution) was investigated as a possible reason for the discrepancy observed in hepatic and intestinal activities (Fig. 3, A and B). Mucosal scraping (Kolars et al., 1994; Paine et al., 1997; Madani et al., 1999) is a mechanical method that generates a mixture of cells in addition to mature enterocytes. The specific activity of P450 enzymes in microsomes prepared by this method is low because some of the enterocytes are lysed and the P450 enzymes may be denatured being exposed to the digestive enzymes (Lin et al., 1999). In contrast, elution with chemically based protease inhibitors is a more gentle isolation technique, is less likely to damage the cells, and results in higher enzyme activity (Lin et al., 1999; Zhang et al., 1999; von Richter et al., 2004).
Comparison of enterocyte isolation methods indicated on average 10-fold greater Vmax values in microsomes from eluted enterocytes compared with mucosal scraping. Comparison of catalytic activities (P450 relative abundance also considered) for 11 different pathways investigated (Fig. 5A) indicated that CYP2C19 activity showed the highest sensitivity on the enterocyte isolation method used (13-29-fold loss in the enzyme activity), followed by CYP3A4, whereas CYP2C9 and CYP2D6 were comparable (Table 2). Overall correction of the clearance estimates obtained in intestinal microsomes prepared by mucosal scraping for the activity loss resulted in comparable (within the 2-fold limit) intrinsic catalytic activities between liver and intestine for two-thirds of the pathways investigated (Fig. 3C). The intestinal clearances of all of the standard CYP3A4 probes (midazolam, testosterone, nifedipine, and quinidine) were within 61 to 136% range of hepatic estimates, whereas in the case of CYP2C9 and CYP2C19, the ratio of intestinal to hepatic clearance ranged from 33 to 73% for tolbutamide and nordiazepam, respectively. These findings represent a significant improvement compared with the 2 to 21% ratio of intestinal to hepatic CLint values obtained from mucosal scraping microsomal data.
Considering the liver-intestine interdonor differences in the current study and the use of mean population values for the P450 relative abundances, we conclude that intestinal and hepatic catalytic activity (per picomole of P450 enzyme) of CYP3A4, CYP2D6, CYP2C9, and CYP2C19 are comparable for a wide range of substrates. The current study indicates the utility of pooled intestinal microsomes in the assessment of intestinal metabolism and establishes an unequivocal relationship between the intrinsic activities of hepatic and intestinal P450 enzymes. For most of the substrates investigated here, efflux transporters contribute to a minor extent in their overall disposition. Hence, it will be important to complement the current work with class 2 substrates from the Biopharmaceutics Drug Disposition Classification System (Wu and Benet, 2005) using intestinal in vitro systems of greater complexity (e.g., transfected cell lines and intestinal slices as in studies by Cummins et al., 2004 and van de Kerkhof et al., 2005, respectively) to adequately assess intestinal metabolism in vitro in the presence of functional transporter proteins.
As is well documented for the liver, prediction of the extent of intestinal first-pass metabolism in vivo from the in vitro data requires an appropriate mechanistic model (e.g., well stirred liver model) to integrate intestinal CLint with many physiological processes. However, there are physiological complexities unique to the intestine; for example, enterocytic rather than organ blood flow needs to be incorporated in addition to the greater cellular heterogeneity and a different spatial arrangement for the P450 enzymes and P-glycoprotein in the intestine compared with the liver. Consensus has yet to be achieved on this modeling issue (Pang, 2003; Benet et al., 2004; Rostami-Hodjegan and Tucker, 2004), and the challenges of a mechanistic approach must be met before intestinal first-pass metabolism in vivo can be confidently predicted from in vitro data on intestinal CLint.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
The work was funded by a consortium of pharmaceutical companies within the Centre for Applied Pharmacokinetic Research at the University of Manchester.
ABBREVIATIONS: P450, cytochrome P450; CLint, intrinsic clearance; HIM, human intestinal microsome(s); LC/MS/MS, liquid chromatography/tandem mass spectrometry; HLM, human liver microsome(s); CLmax, maximal clearance.
Address correspondence to: Dr. Aleksandra Galetin, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK. E-mail: Aleksandra.Galetin{at}manchester.ac.uk
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Benet LZ, Cummins CL, and Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharmaceut 277: 3-9.
Cummins CL, Jacobsen W, Christians U, and Benet LZ (2004) CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 308: 143-155.
Damkier P, Hansen LL, and Brosen K (1999) Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 55: 451-456.[CrossRef][Medline]
Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62: 41-49.[CrossRef][Medline]
Galetin A, Brown C, Hallifax D, Ito K, and Houston JB (2004) Utility of recombinant enzyme kinetics in prediction of human clearance—impact of variability, CYP3A5 and CYP2C19 on CYP3A4 substrates. Drug Metab Dispos 32: 1411-1420.
Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab Dispos 31: 1108-1116.
Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A, von Richter O, Griese EU, et al. (2002) Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 71: 131-140.[CrossRef][Medline]
Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27: 161-166.
Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, and Greenblatt DJ (2001) CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 29: 133-140.
Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, and Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 22: 53-71.[CrossRef][Medline]
Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28: 246-254.
Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4: 247-259.[Medline]
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A4 promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391.[CrossRef][Medline]
Läpple F, von Richetr O, Fromm MF, Richter T, Thon KP, Wisser H, Griese E-U, Eichelbaum M, and Kivistö KT (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13: 565-575.[CrossRef][Medline]
Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42: 1141-1160.[CrossRef][Medline]
Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51: 135-158.
Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal metabolism of midazolam. Mol Pharmacol 62: 162-172.
Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction of erythromycin breath test. Drug Metab Dispos 22: 947-955.[Abstract]
Madani S, Paine MF, Lewis L, Thummel KE, and Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res (NY) 16: 1199-1205.
Masica AL, Mayo G, and Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam and midazolam. Clin Pharmacol Ther 76: 341-349.[CrossRef][Medline]
Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30: 1240-1245.
Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, and Brosen K (1999) In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289: 31-37.
Obach RS, Zhang Q-Y, Dunbar D, and Kaminsky LS (2001) Metabolic characterization of major human small intestinal cytochrome P450s. Drug Metab Dispos 29: 347-352.
Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34: 880-886.
Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependant metabolism. J Pharmacol Exp Ther 283: 1552-1562.
Paine MF, Schmiedlin-Ren P, and Watkins PB (1999) Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 27: 360-364.
Pang KS (2003) Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes. Drug Metab Dispos 31: 1507-1519.
Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, and Vyas KP (1996) Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24: 634-642.[Abstract]
Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, and Houston JB (2005) Microsomal prediction of in vivo clearance and associated inter individual variability of six benzodiazepines in humans. Xenobiotica 35: 603-625.[CrossRef][Medline]
Rostami-Hodjegan A and Tucker GT (2004) `In silico' simulations to assess the `in vivo' consequences of `in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technologies 1: 441-448.
Rowland Yeo K, Rostami-Hodjegan A, and Tucker GT (2003) Abundance of cytochrome P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57: 687-688.
Thörn M, Finnström N, Lundgren S, Rane A, and Lööf L (2005) Cytochromes P450s and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60: 54-60.[CrossRef][Medline]
Thummel KE, Kunze KL, and Shen DD (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27: 99-127.[CrossRef][Medline]
van de Kerkhof EG, de Graaf IAM, de Jager MH, Meijer DKF, and Groothuis GMM (2005) Characterization of rat small intestinal and colon precision-cut slices as an in vitro system for drug metabolism and induction studies. Drug Metab Dispos 33: 1613-1620.
von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, and Kivisto KT (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75: 172-183.[CrossRef][Medline]
Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AYH (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28: 360-366.
Watkins B (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27: 161-170.[CrossRef][Medline]
Wu C-Y and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (NY) 22: 11-23.
Yang J, Tucker GT, and Rostami-Hodjegan A (2004) Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 76: 391.[CrossRef][Medline]
Zhang Q-Y, Dunbar D, Ostrowska A, Zeisloft S, Yang J, and Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27: 804-809.
This article has been cited by other articles:
|
|
 |
|
  J. Henshall, A. Galetin, A. Harrison, and J. B. Houston Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications Drug Metab. Dispos., July 1, 2008; 36(7): 1332 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lofgren, R. M. Baldwin, M. Hiratsuka, A. Lindqvist, A. Carlberg, S. C. Sim, M. Schulke, M. Snait, A. Edenro, R. Fransson-Steen, et al. Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression Drug Metab. Dispos., May 1, 2008; 36(5): 955 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shirasaka, Y. Masaoka, M. Kataoka, S. Sakuma, and S. Yamashita Scaling of in Vitro Membrane Permeability to Predict P-glycoprotein-Mediated Drug Absorption in Vivo Drug Metab. Dispos., May 1, 2008; 36(5): 916 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gertz, P. J. Kilford, J. B. Houston, and A. Galetin Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations Drug Metab. Dispos., March 1, 2008; 36(3): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Gurbel, W. C. Lau, and U. S. Tantry Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel J. Am. Coll. Cardiol., January 22, 2008; 51(3): 261 - 263. [Full Text] [PDF]
|
|
|
|
|
|
A. Di Marco, A. Cellucci, A. Chaudhary, M. Fonsi, and R. Laufer High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin Drug Metab. Dispos., October 1, 2007; 35(10): 1737 - 1743. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
), CYP2C9 (
), CYP2C19 (
), and CYP2D6 (
) pathways investigated. In both panels, the solid line represents line of unity, whereas dashed lines represent either the 2-fold (A) or 50-fold (B) difference between hepatic and intestinal values.
), intestinal microsomes prepared by enterocyte elution (